Efficacy and Safety of Rituximab Combined with Chemotherapy Regimen in Children and Adolescents with Mature B-Cell Non-Hodgkin's Lymphoma: A Systematic Review and Meta-Analysis
Year: 2025
Type: study-registration
Abstract: eview question / Objective To evaluate the efficacy and safety of rituximab combined with chemotherapy compared to chemotherapy alone in improving event-free survival, overall survival, complete remission rate, toxic effects, immune reconstitution, and recurrence rate among children and adolescents aged 0-15 years with mature B-cell non-Hodgkin's lymphoma.Rationale The rationale for this study is driven by the need to improve outcomes for children and adolescents with mature B-cell NHL, the potential benefits of rituximab observed in adult studies, and the necessity to synthesize existing evidence to provide a comprehensive understanding of its efficacy and safety in pediatricpatients.Condition being studied Mature B-cell non-Hodgkin's lymphoma (NHL) is a type of malignancy that originates from mature B-cells, a subset of white blood cells responsible for producing antibodies as part of the immune system.This c o n d i t i o n p r i m a r i l y a ff e c t s c h i l d re n a n d adolescents, representing a significant cause of morbidity and mortality in this age group.The disease is characterized by the uncontrolled proliferation of abnormal B-cells, which can lead to the formation of tumors, systemic symptoms such as fever, weight loss, and fatigue, and, if left untreated, progression to more advanced stages.Common subtypes of mature B-cell NHL in pediatric populations include Burkitt lymphoma, diffuse large B-cell lymphoma, and primary mediastinal large B-cell lymphoma.Early diagnosis and effective treatment are crucial to improving outcomes and reducing the risk of relapse or complications.
Authors: XiuLi Zhu, YuQiao Diao, Yan Chen
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408014666